Our results also indicate that the Myocyte Enhancer Factor-2 genes MEF2A and MEF2D may play more significant roles in FS than PNST or PWT (Fig 5), and that therapeutic strategies that interfere with MEF2 transcriptional activity [89, 90] may be useful in treating FS. The gene discussed is MEF2D; the disease is Feingold syndrome.